Dr. Henry C. Chiou is the product development and business Director of Transfection and Protein Expression within Cell Biology, Life Sciences Solutions at Thermo Fisher Scientific. Some of the more recent technologies for protein expression and gene delivery he and his teams have developed have led to the Expi™ family of 293, CHO and Sf9-based high density expression systems, Lipofectamine™ 3000, RNAiMAX and CRISPR MAX transfection reagents. Henry has authored multiple publications on mammalian transient expression and frequently teaches courses and lectures on this subject. Prior to joining Thermo Fisher, Henry worked in small to mid-sized biotech companies on non-viral gene therapy. Henry received his doctorate from Harvard University in Molecular Pharmacology, following which he completed a post-doctoral fellowship in viral expression systems at the University of Pennsylvania.